GEP20207056B - New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them

Info

Publication number
GEP20207056B
GEP20207056B GEAP201614681A GEAP2016014681A GEP20207056B GE P20207056 B GEP20207056 B GE P20207056B GE AP201614681 A GEAP201614681 A GE AP201614681A GE AP2016014681 A GEAP2016014681 A GE AP2016014681A GE P20207056 B GEP20207056 B GE P20207056B
Authority
GE
Georgia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
bicyclic derivatives
new bicyclic
Prior art date
Application number
GEAP201614681A
Other languages
English (en)
Inventor
Laboratoires Servier Les
Vernalis, (R&D) Ltd
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of GEP20207056B publication Critical patent/GEP20207056B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GEAP201614681A 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them GEP20207056B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555750A FR3037959B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
GEP20207056B true GEP20207056B (en) 2020-01-10

Family

ID=54356456

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201614681A GEP20207056B (en) 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (42)

Country Link
US (2) US10323041B2 (en:Method)
EP (1) EP3313817B1 (en:Method)
JP (1) JP6741699B2 (en:Method)
KR (1) KR102782071B1 (en:Method)
CN (1) CN108137497B (en:Method)
AR (1) AR105102A1 (en:Method)
AU (1) AU2016282828B2 (en:Method)
CA (1) CA2990084C (en:Method)
CL (1) CL2017003205A1 (en:Method)
CO (1) CO2017012832A2 (en:Method)
CR (1) CR20170575A (en:Method)
CU (1) CU24466B1 (en:Method)
CY (1) CY1123645T1 (en:Method)
DK (1) DK3313817T3 (en:Method)
EA (1) EA033566B1 (en:Method)
EC (1) ECSP17083003A (en:Method)
ES (1) ES2831749T3 (en:Method)
FR (1) FR3037959B1 (en:Method)
GE (1) GEP20207056B (en:Method)
HK (1) HK1254656A1 (en:Method)
HR (1) HRP20201782T1 (en:Method)
HU (1) HUE051877T2 (en:Method)
IL (1) IL256375B (en:Method)
JO (1) JO3674B1 (en:Method)
LT (1) LT3313817T (en:Method)
MA (1) MA42230B1 (en:Method)
MD (1) MD3313817T2 (en:Method)
MX (1) MX381707B (en:Method)
PE (1) PE20181491A1 (en:Method)
PH (1) PH12017502315B1 (en:Method)
PL (1) PL3313817T3 (en:Method)
PT (1) PT3313817T (en:Method)
RS (1) RS61179B1 (en:Method)
RU (1) RU2760554C1 (en:Method)
SI (1) SI3313817T1 (en:Method)
SV (1) SV2017005589A (en:Method)
TN (1) TN2017000524A1 (en:Method)
TW (1) TW201712006A (en:Method)
UA (1) UA122498C2 (en:Method)
UY (1) UY36734A (en:Method)
WO (1) WO2016207217A1 (en:Method)
ZA (1) ZA201708562B (en:Method)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CN110381937A (zh) * 2017-01-06 2019-10-25 法国施维雅药厂 Mcl-1抑制剂和紫杉烷化合物的组合及其用途和药物组合物
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
EA202090082A1 (ru) 2017-06-22 2020-05-22 Ле Лаборатуар Сервье Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
AU2018317836A1 (en) * 2017-08-15 2020-03-19 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
WO2019101144A1 (zh) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
WO2019226490A1 (en) 2018-05-22 2019-11-28 Gilead Sciences, Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
KR101973074B1 (ko) 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
CN114728077A (zh) 2019-05-20 2022-07-08 诺华股份有限公司 Mcl-1抑制剂抗体-药物缀合物及使用方法
AR119156A1 (es) 2019-06-17 2021-11-24 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
CA3157015A1 (en) * 2019-10-03 2021-04-08 California Institute Of Technology Mcl1 inhibitors and uses thereof
WO2021142170A1 (en) * 2020-01-09 2021-07-15 University Of Washington Modified pyrrolo- and pyrazolo- pyrimidines for prostate cancer therapy
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
JP2024520801A (ja) 2021-06-11 2024-05-24 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900330A3 (en) 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
EP1922321A1 (en) * 2005-08-09 2008-05-21 Eirx Therapeutics Ltd Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP5781934B2 (ja) * 2008-11-10 2015-09-24 ナショナル ヘルス リサーチ インスティテューツ チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
JP5779102B2 (ja) 2008-12-18 2015-09-16 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺有害生物剤としてのテトラゾール置換アントラニルアミド
ES2535176T3 (es) 2009-09-28 2015-05-06 Qilu Pharmaceutical Co., Ltd Derivados de 4-(anilino sustituido)quinazolina como inhibidores de la tirosina quinasa
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
RU2628616C2 (ru) * 2011-11-03 2017-08-21 Ф. Хоффманн-Ля Рош Аг Бициклические соединения пиперазина
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
AU2016282828A1 (en) 2018-01-18
CU20170163A7 (es) 2018-05-08
CN108137497B (zh) 2021-06-15
MX2017016995A (es) 2018-09-07
MD3313817T2 (ro) 2021-01-31
UA122498C2 (uk) 2020-11-25
EP3313817B1 (en) 2020-09-16
CO2017012832A2 (es) 2018-03-28
EA201890126A1 (ru) 2018-06-29
CL2017003205A1 (es) 2018-06-15
AU2016282828B2 (en) 2020-07-16
PL3313817T3 (pl) 2021-04-06
UY36734A (es) 2016-12-30
CR20170575A (es) 2018-02-20
TW201712006A (zh) 2017-04-01
US10618909B2 (en) 2020-04-14
JP2018527297A (ja) 2018-09-20
HUE051877T2 (hu) 2021-03-29
MA42230A (fr) 2018-05-02
PH12017502315A1 (en) 2018-06-25
US20180258098A1 (en) 2018-09-13
CA2990084A1 (en) 2016-12-29
TN2017000524A1 (en) 2019-04-12
EP3313817A1 (en) 2018-05-02
HRP20201782T1 (hr) 2021-01-22
FR3037959A1 (en:Method) 2016-12-30
NZ738471A (en) 2024-05-31
MX381707B (es) 2025-03-13
DK3313817T3 (da) 2020-12-14
CY1123645T1 (el) 2022-03-24
JO3674B1 (ar) 2020-08-27
ECSP17083003A (es) 2018-02-28
PT3313817T (pt) 2020-11-26
RU2760554C1 (ru) 2021-11-29
AR105102A1 (es) 2017-09-06
EA033566B1 (ru) 2019-11-05
PE20181491A1 (es) 2018-09-18
US20190248805A1 (en) 2019-08-15
HK1254656A1 (zh) 2019-07-26
IL256375B (en) 2020-03-31
CA2990084C (en) 2021-04-13
KR20180015264A (ko) 2018-02-12
CU24466B1 (es) 2020-01-03
SI3313817T1 (sl) 2021-01-29
US10323041B2 (en) 2019-06-18
PH12017502315B1 (en) 2018-06-25
LT3313817T (lt) 2020-11-25
JP6741699B2 (ja) 2020-08-19
KR102782071B1 (ko) 2025-03-14
SV2017005589A (es) 2018-06-01
CN108137497A (zh) 2018-06-08
ZA201708562B (en) 2022-06-29
WO2016207217A1 (en) 2016-12-29
MA42230B1 (fr) 2020-11-30
FR3037959B1 (fr) 2017-08-04
IL256375A (en) 2018-02-28
ES2831749T3 (es) 2021-06-09
RS61179B1 (sr) 2021-01-29

Similar Documents

Publication Publication Date Title
GEP20207056B (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12020550901A1 (en) Macrocyclic compounds for treating disease
GEP201706704B (en) New phosphate compounds, process for their preparation and pharmaceutical compositions containing them
TN2017000529A1 (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MY195977A (en) Heterocyclic Compounds and uses Thereof
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
GEP201706718B (en) Aryl and heteroaryl fused lactams
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
GEP201706686B (en) Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MD20150091A2 (ro) Compuşi antivirali
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
MY197440A (en) Heteroamatic compounds as btk inhibitors
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX2017014035A (es) Formas solidas novedosas.
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
NZ740119A (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide